DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (20)
2023
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
-
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615
2022
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097
-
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
European Urology, Vol. 81, Núm. 3, pp. 266-271
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
European Journal of Cancer, Vol. 172, pp. 340-348
-
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
ESMO Open, Vol. 7, Núm. 5
2021
-
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
BJU International, Vol. 128, Núm. 2, pp. 196-205
-
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Vol. 17, Núm. 2, pp. 137-149
2020
-
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet, Vol. 395, Núm. 10241, pp. 1907-1918
-
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Cancer Treatment Reviews, Vol. 89
-
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 785-786
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial
ESMO Open, Vol. 5, Núm. 6
-
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Cancer, Vol. 126, Núm. 18, pp. 4156-4167
2018
-
Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))
European Urology
-
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]
European Urology
-
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma
New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290
2017
-
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]
European Urology, Vol. 72, Núm. 6, pp. 962-971
2015
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
New England Journal of Medicine, Vol. 373, Núm. 19, pp. 1803-1813